Tumor mutational burden is associated with poor outcomes in diffuse glioma

被引:0
作者
Lihong Wang
Jia Ge
Yang Lan
Yu Shi
Ying Luo
Yuhuan Tan
Mei Liang
Song Deng
Xia Zhang
Wenying Wang
Yaoyao Tan
Yuanyuan Xu
Tao Luo
机构
[1] Third Military Medical University (Army Medical University) and Key Laboratory of Tumor Immunopathology,Institute of Pathology and Southwest Cancer Center, Southwest Hospital
[2] Ministry of Education of China,Bio
[3] Third Military Medical University (Army Medical University),Bank of Southwest Hospital
来源
BMC Cancer | / 20卷
关键词
TMB; Glioma; Prognosis; Pan-cancer targeted sequencing;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 228 条
[1]  
Brat DJ(2015)Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas N Engl J Med 372 2481-2498
[2]  
Verhaak RG(2016)Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse Glioma Cell 164 550-563
[3]  
Aldape KD(2015)Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors N Engl J Med 372 2499-2508
[4]  
Yung WK(2016)The 2016 World Health Organization classification of tumors of the central nervous system: a summary Acta Neuropathol 131 803-820
[5]  
Salama SR(2019)Tumor mutational load predicts survival after immunotherapy across multiple cancer types Nat Genet 51 202-206
[6]  
Cooper LA(2018)Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy Science 362 eaar3593-3006
[7]  
Rheinbay E(2018)Tumor mutation burden as a biomarker in resected non-small-cell lung Cancer J Clin Oncol 36 2995-699
[8]  
Miller CR(2018)Clinical Impact of Tumor Mutational Burden in Neuroblastoma JNCI: Journal of the National Cancer Institute 111 695-1236
[9]  
Vitucci M(2017)Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden Genome Med 9 34-641
[10]  
Ceccarelli M(2016)Immunogenomics of Hypermutated Glioblastoma: a patient with Germline POLE deficiency treated with checkpoint blockade immunotherapy Cancer Discov 6 1230-421